Paolo Tarantino says Dato-DXd in TROPION-Breast02 nearly doubled progression-free survival and response rate and improved overall survival versus chemotherapy in IO-ineligible metastatic triple negative breast cancer.
TROPION-Breast02 published in Annals_Oncology: 1L therapy with Dato-DXd led to near doubling of PFS, ORR and significant OS benefit (vs chemo) in IO-ineligible mTNBC.
New important option and new hope for one of the most aggressive forms of breast cancer.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare